Tarsus Pharmaceuticals
Irvine, California, United States · Biopharma, Biotechnology, Health Care
Tarsus Pharmaceuticals, Inc. is a company specializing in biological products. They have shown substantial growth and have strategic initiatives in place, including the recent appointment of Dr. Elizabeth Yeu as the new Chief Medical Officer.
You have opened 5 full company profiles today. Create an account to keep reading them. Create an account
Key facts
- Headquarters
- Irvine, California, United States
- Employees
- 370
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Public (TARS)
- Website
- tarsusrx.com
- Company page
Recent activity at Tarsus Pharmaceuticals
- : SEC 8-K (2.01): On September 4, 2026, Tarsus Pharmaceuticals, Inc. completed its acquisition of Alkeus Pharmaceuticals, Inc. through a merger, finalizing a transaction valued at approximately $270 million in cash and stock. Along with the initial consideration, Tarsus has committed to pay up to $350 million in milestone payments upon achieving regulatory approval for Alkeus products and an additional $100 million upon their first sale in the U.S. The acquisition was executed through a specified Agreement and Plan of Merger, marking a significant expansion of Tarsus's portfolio. This strategic move allows Tarsus to integrate Alkeus's assets and products, potentially enhancing their market position. The financial terms illustrate substantial future growth potential contingent upon product approvals and sales.
- : Tarsus Pharmaceuticals to acquire Alkeus Pharmaceuticals
- : Tarsus Pharmaceuticals secures $125.0 million in oversubscribed Private Placement Equity Financing, led by Barclays with participation from TCGX and Bain Capital. The funds will support clinical development and corporate activities.
Employee benefit plans
Tarsus Pharmaceuticals files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
About Tarsus Pharmaceuticals: questions and answers
What does Tarsus Pharmaceuticals do?
Tarsus Pharmaceuticals, Inc. is a company specializing in biological products. They have shown substantial growth and have strategic initiatives in place, including the recent appointment of Dr. Elizabeth Yeu as the new Chief Medical Officer.
Where is Tarsus Pharmaceuticals headquartered?
Tarsus Pharmaceuticals is headquartered in Irvine, California, United States.
How many employees does Tarsus Pharmaceuticals have?
Tarsus Pharmaceuticals has about 370 employees.
What is the latest news on Tarsus Pharmaceuticals?
On Sep 10, 2026, SEC 8-K (2.01): On September 4, 2026, Tarsus Pharmaceuticals, Inc. completed its acquisition of Alkeus Pharmaceuticals, Inc. through a merger, finalizing a transaction valued at approximately $270 million in cash and stock. Along with the initial consideration, Tarsus has committed to pay up to $350
Is Tarsus Pharmaceuticals a public company?
Yes. Tarsus Pharmaceuticals is publicly traded under the ticker TARS.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy